Preview

Медицинский Совет

Расширенный поиск

ВОЗМОЖНОСТИ ПРИМЕНЕНИЯ РАДИЯ-223 В ЛЕЧЕНИИ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ

https://doi.org/10.21518/2079-701X-2017-6-118-122

Полный текст:

Аннотация

В последние годы было разработано несколько терапевтических вариантов, значительно повышающих выживаемость пациентов с метастатическим кастрационно-резистентным РПЖ (мКРРПЖ). Наличие нескольких активных агентов предоставляет онкологам беспрецедентную возможность адаптировать свой выбор к клиническим характеристикам каждого пациента, к каждой линии лечения, но в то же время создает проблему определения оптимальной терапевтической последовательности для отдельного больного. Вследствие эволюции стратегии лечения, сложности процесса оценки динамики лечения и вариабельности клинических аспектов заболевания мультидисциплинарный подход приобретает сегодня первостепенное значение. В настоящей статье представлены мнения и рекомендации экспертной междисциплинарной группы (Милан, Италия) по использованию радия-223 у мужчин с мКРРПЖ.

Об авторах

А. А. ГРИЦКЕВИЧ
Институт хирургии им. А.В. Вишневского
Россия
к.м.н.


С. В. МИШУГИН
Городская клиническая больница №57
Россия
к.м.н.


И. Г. РУСАКОВ
Городская клиническая больница №57 Национальный медицинский исследовательский радиологический центр
Россия
д.м.н., профессор


Список литературы

1. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2017: 12-36.

2. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N et al. 2000. Metastatic patterns of prostate cancer: an autopsy studyof 1,589 patients. Hum. Pathol., 31(5): 578-583.

3. Scher HI, Morris MJ, Basch E, Heller G. End points and outcomes incastration-resistant prostate cancer: from clinical trials to clinical practice. J. Clin. Oncol., 2011, 29(27): 3695-3704.

4. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. 2004. Docetaxel plus prednisone or mitoxantrone plusprednisone for advanced prostate cancer. N. Engl. J. Med., 351(15): 1502-1512.

5. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I et al. Prednisone plus cabazitaxel or mitoxantrone formetastatic castration- resistant prostate cancer progressing after docetaxeltreatment: a randomised openlabel trial. Lancet, 2010, 376(9747): 1147- 1154.

6. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS et al. 2014. Enzalutamidein metastatic prostate cancer before chemotherapy. N. Engl. J. Med., 371(5): 424-433.

7. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L et al. Abiraterone and increased survival in metastaticprostate cancer. N. Engl. J. Med., 2011, 364(21): 1995-2005.

8. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza, P et al. 2013. Abiraterone in metastatic prostatecancer without previous chemotherapy. N. Engl. J. Med., 368(2): 138-148.

9. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al. Increased survival with enzalutamide inprostate cancer after chemotherapy. N. Engl. J. Med., 2012, 367(13): 1187-1197.

10. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD et al. Alpha emitter radium-223 and survival inmetastatic prostate cancer. N. Engl. J. Med., 2013, 369(3): 213- 223.

11. Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M et al. 2015. Androgenreceptor splice variant 7 and efficacy of taxane chemotherapy in patients withmetastatic castrationresistant prostate cancer. JAMA Oncol., 1(5): 582-591.

12. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC et al. AR-V7 and resistance to enzalutamide andabiraterone in prostate cancer. N Engl J Med, 2014, 371(11): 1028- 1038.

13. Thadani-Mulero M, Portella L, Sun S, Sung M, Matov A, Vessella RL et al. 2014. Androgen receptor splicevariants determine taxane sensitivity in prostate cancer. Cancer Res, 74(8): 2270-2282.

14. Caffo O, Lunardi A, Trentin C, Maines F, Veccia A, Galligioni E. Optimalsequencing of new drugs in metastatic castration-resistant prostate cancer: Dream or reality? Curr. Drug Targets, 2016, 17(11): 1301-1308.

15. Carrasquillo, JA, O’Donoghue, JA, Pandit-Taskar, N, Humm, JL, Rathkopf, DE, Slovin, SF et al. 2013. Phase I pharmacokinetic and biodistribution study withescalating doses of (2)(2) (3) Ra-dichloride in men with castration-resistantmetastatic prostate cancer. Eur. J. Nucl. Med. Mol. Imaging, 40(9): 1384-1393.

16. Suominen MI, Rissanen JP, Kakonen R, Fagerlund KM, Alhoniemi E, Mumberg D et al. Survival benefit with radium-223 dichloride in a mouse model of breast cancerbone metastasis. J. Natl. Cancer Inst., 2013, 105(12): 908-916.

17. Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM et al. Effect of radium- 223 dichlorideon symptomatic skeletal events in patients with castration-resistant prostatecancer and bone metastases: results from a phase 3, double-blind, randomisedtrial. Lancet Oncol., 2014, 15(7): 738-746.

18. Hoskin, P, Sartor, O, O’Sullivan, JM, Johannessen, DC, Helle, SI, Logue, J,Bottomley, D et al. 2014. Efficacy and safety of radium-223 dichloride in patients withcastration-resistant prostate cancer and symptomatic bone metastases, withor without previous docetaxel use: a prespecified subgroup analysis from therandomised, double- blind, phase 3 ALSYMPCA trial. Lancet Oncol., 15(12): 1397-1406.

19. Nilsson S, Tomblyn M, Cislo P. Patient-reported quality of life analysis ofradium-223 dichloride evaluating pain relief from the phase 3 ALSYMPCAstudy. J. Clin. Oncol., 2014, 32: 5069, Abstract.

20. Cislo P, Sartor AO, Reuning-Scherer J. Effects of radium-223 dichloride onhealth-related quality of life assessed by the EQ-5D utility scores inALSYMPCA. Eur. Urol., 2015, 14: e673- e773.

21. Nilsson S, Cislo P, Sartor O, Vogelzang NJ, Coleman RE, O’Sullivan JM et al. Patientreportedquality- of-life analysis of radium-223 dichloride from the phase III ALSYMPCAstudy. Ann. Oncol., 2016, 27(5): 868-874.

22. Sartor, AO, Fernandez, DC, Morris, MJ, Iagaru, A, Brown, A, Almeida, F, et al. 2015a. Ra- 223 experience in pretreated patients: EAP setting. J. Clin. Oncol. 33 (Suppl): 5063, Abstract.

23. Saad F, Keizman D, O’Sullivan JM, Carles J, Wirth M, Gillessen S et al. Analysis ofoverall survival by number of radium-223 injections received in aninternational expanded access program (iEAP). Clin. Oncol., 2016, 34(15 suppl): 5082, abstract.

24. Graff JN, Beer TM. Pharmacotherapeutic management of metastatic,castration- resistant prostate cancer in the elderly: focus on nonchemotherapyagents. Drugs Aging, 2014, 31(12): 873-882.

25. Sartor AO, Heinrich D, Mariados N, Radium-223 (Ra-223) re-treatment(Re-tx): First experience from an international, multicenter, prospective studyin patients (Pts) with castration-resistant prostate cancer and bone metastases(mCRPC). J. Clin. Oncol., 2016, 34(Suppl 2S): 197, Abstract.

26. Fizazi K, Massard C, Smith M, Rader M, Brown J, Milecki P et al. Bone-related parameters are the main prognostic factors for overall survival inmen with bone metastases from castrationresistant prostate cancer. Eur. Urol., 2015, 68(1): 42-50.

27. Sartor AO, Amariglio R, Wilhelm S, Garcia-Vargas J, O’Bryan-Tear CG, Shan M et al. Correlation between baseline variables andsurvival in the radium-223 dichloride (Ra-223) phase III ALSYMPCA trial withattention to total ALP changes. J. Clin. Oncol., 2013, 31(15 Suppl): 5080.

28. Nilsson S, Franzen L, Parker C, Tyrrell C, Blom R, Tennvall J et al. Bone-targetedradium- 223 in symptomatic, hormone-refractory prostate cancer: arandomised, multicentre, placebo-controlled phase II study. Lancet Oncol., 2007, 8(7): 587-594.

29. Nome R, Hernes E, Bogsrud TV, Bjoro T, Fossa SD, Changes inprostate-specific antigen, markers of bone metabolism and bone scans aftertreatment with radium-223. Scand. J. Urol., 2015, 49(3): 211-217.

30. Etchebehere EC, Milton DR, Araujo JC, Swanston NM, Macapinlac HA, Rohren EM. Factors affecting (223)Ra therapy: clinical experienceafter 532 cycles from a single institution. Eur. J. Nucl. Med. Mol. Imaging, 2016, 43(1): 8-20.

31. Kelloff GJ, Coffey DS, Chabner BA, Dicker AP, Guyton KZ, Nisen PD et al. Prostate- specific antigen doubling time as asurrogate marker for evaluation of oncologic drugs to treat prostate cancer. Clin. Cancer Res., 2004, 10(11): 3927-3933.

32. Parker C, Finkelstein SE, Michalski JM, O’Sullivan JM, Bruland O, Vogelzang NJ et al. Efficacy and safety of radium-223 dichloride in symptomaticcastration-resistant prostate cancer patients with or without baseline opioiduse from the phase 3 ALSYMPCA trial. Eur. Urol., 2016, 70(5): 875–883.

33. Sartor AO, Fernandez DC, Morris MJ, Iagaru A, Brown A, Almeida et al. Radium-223 dichloride experience inpretreated patients: early access program. J. Clin. Oncol., 2015, 31(Suppl): 5068, Abstract.

34. Morris MJ, Higano CS, Scher H, Sweeney C, Antonarakis ES, Shevrin DH et al. Effects of radium-223 dichloride(Ra-223) with docetaxel (D) versus D on prostate-specific antigen (PSA) andbone alkaline phosphatase (bALP) in patients (pts) with castration- resistantprostate cancer (CRPC) and bone metastases (mets): A phase 1/2a clinical trial. J. Clin. Oncol., 2015, 34(Supply 7): 202, Abstract.

35. Sartor O, Hoskin P, Coleman RE, Nilsson S, Vogelzang NJ, Petrenciuc O, et al. Chemotherapy followingradium-223 dichloride treatment in ALSYMPCA. Prostate, 2016, 76(10): 905-916.


Для цитирования:


ГРИЦКЕВИЧ А.А., МИШУГИН С.В., РУСАКОВ И.Г. ВОЗМОЖНОСТИ ПРИМЕНЕНИЯ РАДИЯ-223 В ЛЕЧЕНИИ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ. Медицинский Совет. 2017;(6):118-122. https://doi.org/10.21518/2079-701X-2017-6-118-122

For citation:


GRITSKEVICH A.A., MISHUGIN S.V., RUSAKOV I.G. POSSIBILITIES OF RADIUM-223 APPLICATION IN THERAPY OF PROSTATE GLAND CANCER. Medical Council. 2017;(6):118-122. (In Russ.) https://doi.org/10.21518/2079-701X-2017-6-118-122

Просмотров: 131


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)